-
公开(公告)号：EP3047275B1
公开(公告)日：2020-11-18
申请号：EP14842369.2
申请日：2014-09-05
申请人： Consejo Nacional De Investigaciones Cientificas Y Tecnicas , Asociación Civil De Estudios Superiores , Inis Biotech LLC
IPC分类号： A61P35/00 , C12N5/0775
-
公开(公告)号：EP3041861B1
公开(公告)日：2019-03-27
申请号：EP14790721.6
申请日：2014-09-05
申请人： Inis Biotech LLC , Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET) , Fundacion Instituto Leloir (FIL) , Asociación Civil De Estudios Superiores
发明人： MAZZOLINI, Guillermo Daniel , PEIXOTO, Estanislao , AQUINO, Jorge , ATORRASAGASTI, María C. , PODHJACER, Osvaldo
IPC分类号： C07K14/47 , C12N15/113 , C07K16/18
-
公开(公告)号：EP4422642A1
公开(公告)日：2024-09-04
申请号：EP22801892.5
申请日：2022-10-24
申请人： Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) , Asociación Civil de Estudios Superiores - Universidad Austral , Universidad Nacional de La Pampa
发明人： BRECCIA, Javier Darío , WEIZ, Gisela , MOLEJÓN, María Inés , MAZZAFERRO, Laura Soledad , MALVICINI, Mariana , MAZZOLINI RIZZO, Guillermo Daniel
IPC分类号： A61K31/7048 , A61P35/00
CPC分类号： A61K31/7048 , A61P35/00
-
4.发明授权SYNERGIC PHARMACEUTICAL COMPOSITION, USEFUL FOR INHIBITING CORNEAL AND RETINAL NEOVASCULARIZATION (ANGIOGENESIS), AND IN OTHER ORGANS, IN A HUMAN BEING OR ANIMAL 有权Synerge药物组合物用于抑制角膜和视网膜新血管形成（血管生成）及其他机构的人或动物
公开(公告)号：EP2186529B1
公开(公告)日：2012-03-28
申请号：EP08793787.6
申请日：2008-08-07
CPC分类号： A61K31/185 , A61K31/167 , A61K39/3955 , A61K45/06 , C07C309/35 , C07C309/47 , C07K16/22 , A61K2300/00
摘要： A synergic pharmaceutical composition, useful for inhibiting human or animal neovascularization (angiongenesis) of the cornea, retina and other organs, characterized in that it comprises, in a pharmaceutically acceptable vehicle or carrier: 60 to 90% in weight of Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10% of Bevacizumab; wherein said percentages are with respect to the sum of the weights of both active principles. Said synergic pharmaceutical composition is presented in the form of an composition injectable by endovenous, intravitreous or subconjunctival route, or in the form for topical administration.
-
5.发明公开COMPOSITIONS AND METHODS FOR INCREASING MESENCHYMAL STROMAL CELL MIGRATION TO TUMORS 审中-公开ZUSAMMENSETZUNGEN UND VERFAHREN ZURERHÖHUNGDER MESENCHYMALEN STRMAZELLMIGRATION ZU TUMOREN
公开(公告)号：EP3047275A4
公开(公告)日：2017-01-25
申请号：EP14842369
申请日：2014-09-05
申请人： CONSEJO NAC DE INVESTIG CIENTIFICAS Y TECN , ASOCIACIÓN CIVIL DE ESTUDIOS SUPERIORES , INIS BIOTECH LLC
IPC分类号： C12N5/0775 , A61K35/28 , C12N5/077
CPC分类号： A61K35/28 , C12N5/0668 , C12N5/0669 , C12N2501/20 , C12N2501/40 , C12N2501/998 , C12N2502/99
摘要： The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.
摘要翻译： 本申请涉及用癌症治疗受试者和/或增加用重组自分泌运动因子（rAMF）刺激的间充质基质细胞（MSC）向肿瘤或肿瘤细胞例如移植物的迁移的组合物和方法。 肝细胞癌（HCC）。 此外，公开了通过rAMF增加MSC对内皮细胞粘附的方法。 在一些实施方案中，MSC包含治疗剂，例如抗肿瘤剂。
-
6.发明公开COMPOSITIONS AND METHODS FOR INCREASING MESENCHYMAL STROMAL CELL MIGRATION TO TUMORS 审中-公开组合物和方法增质STROMAZELLMIGRATION肿瘤
公开(公告)号：EP3047275A1
公开(公告)日：2016-07-27
申请号：EP14842369.2
申请日：2014-09-05
申请人： Consejo Nacional De Investigaciones Cientificas Y Tecnicas , Asociación Civil De Estudios Superiores , Inis Biotech LLC
IPC分类号： G01N33/574
摘要： The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.
-
7.发明公开SPARC (SECRETED PROTEIN, ACIDIC AND RICH IN CYSTEINE), A NEW TARGET FOR THE TREATMENT AND PREVENTION OF ACUTE LIVER FAILURE 审中-公开SPARC（酸性分泌蛋白富含半胱氨酸），一个新的目标，用于治疗和预防急性肝机能不全
公开(公告)号：EP3041861A2
公开(公告)日：2016-07-13
申请号：EP14790721.6
申请日：2014-09-05
申请人： Inis Biotech LLC , Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET) , Fundacion Instituto Leloir (FIL) , Asociación Civil De Estudios Superiores
发明人： MAZZOLINI, Guillermo Daniel , PEIXOTO, Estanislao , AQUINO, Jorge , ATORRASAGASTI, María C. , PODHJACER, Osvaldo
IPC分类号： C07K14/47 , C12N15/113 , C07K16/18
CPC分类号： C07K14/78 , C07K16/18 , C07K2317/76 , C12N15/113 , C12N15/86 , C12N2310/11 , C12N2310/14 , C12N2710/10043 , C12N2740/15043
摘要： The invention relates to the identification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of SPARC and/or interferes with its biological function.
摘要翻译： 本发明涉及一种在半胱氨酸（SPARC）鉴定分泌蛋白，酸性和Rich的作为患者暴发性肝炎治疗的新靶点和允许去往保护肝脏损伤形式的策略的发展。 本发明通过给予需要其的受试者的药剂确实抑制至少部分SPARC的表达和/或与它的生物学功能干扰涉及急性肝功能衰竭或暴发性肝炎的治疗。
-
8.发明公开SYNERGIC PHARMACEUTICAL COMPOSITION, USEFUL FOR INHIBITING CORNEAL AND RETINAL NEOVASCULARIZATION (ANGIOGENESIS), AND IN OTHER ORGANS, IN A HUMAN BEING OR ANIMAL 有权Synerge药物组合物用于抑制角膜和视网膜新血管形成（血管生成）及其他机构的人或动物
公开(公告)号：EP2186529A2
公开(公告)日：2010-05-19
申请号：EP08793787.6
申请日：2008-08-07
CPC分类号： A61K31/185 , A61K31/167 , A61K39/3955 , A61K45/06 , C07C309/35 , C07C309/47 , C07K16/22 , A61K2300/00
摘要： A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
摘要翻译： 的协同药物组合物可用于抑制角膜和视网膜neovasculization（血管生成），并在其它器官中的人或动物，在包含表征，在药学上可接受的赋形剂或载体：60〜90重量％Suramine，或一个相当于 物的药学上可接受的盐; 和40至10重量％的贝伐单抗; worin所述百分比都是相对于另外两个重量活性校长的。 所述协同药物组合物是可注射组合物的通过静脉内，intravitrea或subconjuntival装置或下的形式用于局部给药的形式下。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.012 秒)
